Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODESIX INCBDSX · Entity 6053 | Director | January 02, 2026 | January 06, 2026 |
| Dimension Therapeutics, Inc.DMTX · Entity 172012 | Chief Financial Officer | February 01, 2017 | February 03, 2017 |
| Disc Medicine, Inc.IRON · Entity 2273 | Chief Financial Officer | April 13, 2026 | April 15, 2026 |
| MERRIMACK PHARMACEUTICALS INCMACK · Entity 95770 | Chief Financial Officer | December 11, 2018 | December 13, 2018 |
| Replimune Group, Inc.REPL · Entity 4707 | Chief Financial Officer | May 16, 2023 | May 19, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODESIX INC
Report date January 02, 2026 · Filed January 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 8,164 |
Reported balance
After 2026-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-02 · Grant · Acquired 8,164 · Balance 8,164 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.46 · Expires 2036-01-01 | Direct | 6,354 |
Reported balance
After 2026-01-02 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-02 · Grant · Acquired 6,354 · Balance 6,354 F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
F2: These RSUs vest in four equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
F3: Represents deferred RSUs. The shares of Common Stock underlying these RSUs will be issued to the Reporting Person following the Reporting Person's separation from service with the Issuer.
F4: This option vests in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer.
Dimension Therapeutics, Inc.
Report date February 01, 2017 · Filed February 03, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.90 · Expires 2027-01-31 | Direct | 60,000 |
Reported balance
After 2017-02-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-01 · Grant · Acquired 60,000 · Balance 60,000 F1: This stock option vests in forty-eight (48) equal monthly installments beginning on January 18, 2017. |
Filing footnotes · ownership attribution and instrument terms
F1: This stock option vests in forty-eight (48) equal monthly installments beginning on January 18, 2017.
Disc Medicine, Inc.
Report date April 13, 2026 · Filed April 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,333 |
Ending reported balance
After 2026-04-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-13 · Sale · Disposed 400 · Balance 70,590 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025. Row 2 · 2026-04-14 · Sale · Disposed 6,257 · Balance 64,333 F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $69.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4. |
Filing footnotes · ownership attribution and instrument terms
F1: These transactions were effected by the Reporting Person pursuant to a Rule 10b5-1 trading plan adopted on September 25, 2025.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $69.07 to $69.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
MERRIMACK PHARMACEUTICALS INC
Report date December 11, 2018 · Filed December 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.15 · Expires 2028-12-10 | Direct | 45,000 |
Reported balance
After 2018-12-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-12-11 · Grant · Acquired 45,000 · Balance 45,000 F1: This option vests as to 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21. |
Filing footnotes · ownership attribution and instrument terms
F1: This option vests as to 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21.
Replimune Group, Inc.
Report date May 16, 2023 · Filed May 19, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 128,748 |
Reported balance
After 2023-05-16 transaction · row 1
1 source rowRow 1 · 2023-05-16 · Sale · Disposed 11,351 · Balance 128,748 F1: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person. F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.23. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock sold to cover tax withholding obligations in connection with the partial vesting of the Reporting Person's Restricted Stock Units ("RSU"). The transaction reported herein was made in accordance with the irrevocable "sell to cover" provision set forth in the award agreement under which the RSU was granted and does not represent a discretionary sale by the Reporting Person.
F2: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.05 to $18.23. The Reporting Person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 14, 2020 Filed Dec 17, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 6,755 | $42.86 | $289,519.30 |
DisclosureSEC source: 0001104659-20-136479 · tm2038707d1_4.xml · nonDerivative · entry 3 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 389 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.24 to $43.21. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | SaleCommon Stock | 17,856 | $43.70 | $780,307.20 |
DisclosureSEC source: 0001104659-20-136479 · tm2038707d1_4.xml · nonDerivative · entry 2 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,144 F1 · kind: The sales reported on this Form 4 were made by the reporting person pursuant to a trading plan adopted on November 13, 2020 that is intended to comply with Rule 10b5-1(c) under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported reflects a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.22 to $44.21. The reporting person will provide to the Issuer, any security holder of the Issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| December 14, 2020 Filed Dec 17, 2020 02:00 UTC | Replimune Group, Inc. REPL · Entity 4707 | Exercise / conversionCommon Stock | 25,000 | $14.08 | $352,000.00 |
DisclosureSEC source: 0001104659-20-136479 · tm2038707d1_4.xml · nonDerivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2020 Filed Apr 2, 2020 20:34 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 56,350 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0001104659-20-042509 · a4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,350 Underlying: Common Stock · 56,350 shares Expires 2030-04-01 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on April 1, 2021, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 23:02 UTC | Replimune Group, Inc. REPL · Entity 4707 | GrantEmployee Stock Option (right to buy) · Derivative | 180,000 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0001104659-19-071921 · a4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2029-12-09 F1 · derivative.exercise_date: 25% of the shares underlying this stock option vest on December 9, 2020, and the remainder of the shares underlying this stock option vest in 36 approximately equal monthly installments thereafter. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 16:16 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $4.15 | $0.00 |
DisclosureSEC source: 0001209191-18-062435 · doc4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-12-10 F1 · derivative.exercise_date: This option vests as to 1/12th of the total number of shares granted on 3/11/19 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 12/11/21. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 16:08 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $10.74 | $0.00 |
DisclosureSEC source: 0001209191-18-010811 · doc4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2028-02-14 F1 · derivative.exercise_date: This option vests as to 1/12th of the total number of shares granted on 5/15/18 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 2/15/21. Read SEC document |
| August 24, 2017 Filed Aug 28, 2017 16:54 UTC | MERRIMACK PHARMACEUTICALS INC MACK · Entity 95770 | GrantStock Option (right to buy) · Derivative | 450,000 | $0.00 Strike: $1.32 | $0.00 |
DisclosureSEC source: 0001209191-17-050426 · doc4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,000 Underlying: Common Stock · 450,000 shares Expires 2027-08-23 F1 · derivative.exercise_date: This option vests as to 1/6th of the total number of shares granted on 2/21/18 and an additional 1/12th of the total number of shares granted at the end of each successive three month period thereafter until 8/21/20. Read SEC document |
| February 01, 2017 Filed Feb 3, 2017 16:39 UTC | Dimension Therapeutics, Inc. DMTX · Entity 172012 | GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $1.90 | $0.00 |
DisclosureSEC source: 0001209191-17-007647 · doc4.xml · derivative · entry 1 Franchi Jean M. · CIK 0001653053 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-01-31 F1 · derivative.exercise_date: This stock option vests in forty-eight (48) equal monthly installments beginning on January 18, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.